Loading
Geron Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 13 May 2025.
Geron Corp: what insiders have been doing
Geron Corp, founded in 1990, is a Healthcare & Pharma company based in Menlo Park, United States. Its directors and officers file their transactions with SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Geron Corp logged 4 filings by 2 insiders.
The filings describe grants, exercises and other transfers rather than trades on the open market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
No insider has bought Geron Corp shares on the open market in the past twelve months. Typically, a trade is published a median of 1 day after it takes place. The legal deadline for a Form 4 is two business days after the transaction.
With 4 filings in twelve months, the company is quieter than the median of 19 filings across the 5,812 companies we follow on the same exchange. The full history, which starts in 2016, counts 5 purchases against no sales.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
51
Thresholds
n/a
Buy Volume
€224,511
5 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleJames Ziegler1 buy
John A. Scarlett1 buy
Scott Alan Samuels1 buy
V. Bryan Lawlis1 buy
Since the insiders bought
- +17.6%Entry US$1.19 · Close at T+365 US$1.40
- -11.4%Entry US$1.66 · Close at T+365 US$1.47
- -11.4%Entry US$1.66 · Close at T+365 US$1.47
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,966 of 24,158 companies
25.3
score / 100
Value14
Quality37
FCF yld-15%
Earn yld-11%
EV/EBITDA·
ROE-28%
Gross mgn97%
Net mgn-45%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.19
Analyst consensus
4 analysts1.60/5
US$3.00Target US$4.25(+257%)US$6.00
Income statement
RevenueUS$183.9M
Gross profitUS$179.1M97% margin
EBITDA-US$49.6M-27% margin
Net income-US$83.5M-33.1% margin
Valuation
PER (forward)29.8x
P/Book3.5x
Beta0.61
Balance sheet & cash
Market capUS$764.5M
Total debtUS$122M
Free Cash Flow-US$111.1M
Debt / Equity56%
Profitability & ownership
ROE-28.3%
ROA-4.1%
% insiders0.1%
% institutions77.1%
Last declaration on 1 October 2026
Declarations51 total
6,351 shares@ US$1.230.0008% mcap12.4% of flowCommon StockSEC:0001492256-26-000009:0
5,243 shares@ US$1.4913.9% of flowCommon StockSEC:0001492256-26-000004:0
27,500 shares0Common StockSEC:0001755098-26-000001:0
5,918 shares@ US$1.3213.7% of flowCommon StockSEC:0001492256-26-000003:0
5,702 shares@ US$1.3713.7% of flowCommon StockSEC:0001628280-25-043459:0
5,540 shares@ US$1.4113.6% of flowCommon StockSEC:0000886744-25-000038:0
13,300 shares@ US$1.17812.5% of flowCommon StockSEC:0000886744-25-000013:0
Canonical exit: 7 Aug 2025 (T+90)
1,767 shares@ US$4.5414.8% of flowCommon StockSEC:0000950170-25-049544:0
4,913 shares@ US$1.5914.9% of flowCommon StockSEC:0000950170-25-049594:0
2,206 shares@ US$3.5415.4% of flowCommon StockSEC:0000950170-25-049554:0
2,462 shares@ US$3.3025.6% of flowCommon StockSEC:0000950170-25-049533:0
100,000 shares@ US$1.60100.0% of flowCommon StockSEC:0000950170-25-030327:0
Canonical exit: 28 May 2025 (T+90)
12,500 shares@ US$1.7651.0% of flowCommon StockSEC:0000950170-25-030329:0
Canonical exit: 28 May 2025 (T+90)
15,000 shares@ US$1.61100.0% of flowCommon StockSEC:0000950170-25-030330:0
Canonical exit: 28 May 2025 (T+90)
2,206 shares0Common StockSEC:0000950170-25-000409:0
1,767 shares0Common StockSEC:0000950170-24-110796:0
674,348 shares@ US$1.7283.3% of flowCommon StockSEC:0000950170-24-082686:0
2,462 shares0Common StockSEC:0000950170-24-079169:0
421,875 shares@ US$1.0692.4% of flowCommon StockSEC:0000950170-24-072418:0
112,500 shares@ US$1.06100.0% of flowCommon StockSEC:0000950170-24-072420:0
600,000 shares@ US$2.5468.5% of flowCommon StockSEC:0000950170-24-069289:0
35,000 shares@ US$1.9455.9% of flowCommon StockSEC:0000950170-24-061615:0
6,220 shares0Common StockSEC:0001209191-24-000546:0
3,406 shares0Common StockSEC:0001209191-24-000547:0
1,970 shares0Common StockSEC:0001209191-24-000545:0
25 of 51 declarations
About Geron Corp
Geron Corp. (NASDAQ: GERN) is a U.S.-based commercial-stage biopharmaceutical company focused on blood cancers. Headquartered in Foster City, California, United States, the company was founded in 1990 and built its scientific identity around telomerase inhibition, a differentiated biological approach aimed at limiting malignant cell proliferation. For international investors, Geron is notable because it has moved from being primarily a development-stage biotech to a revenue-generating commercial company, which changes both the opportunity set and the risk profile.
The company’s lead asset is RYTELO® (imetelstat), which Geron describes as a first-in-class telomerase inhibitor. In the United States, RYTELO is marketed for certain patients with lower-risk myelodysplastic syndromes who have transfusion-dependent anemia. This product is now the central engine of Geron’s commercial story and the main source of reported product revenue. Beyond the approved indication, the company is also advancing imetelstat in myelofibrosis through phase 3 studies, making the pipeline highly concentrated but potentially meaningful if additional indications are validated.
Read moreShow less
From a competitive standpoint, Geron operates in a demanding hematology-oncology market where treatment standards are well established and clinical differentiation matters greatly. Its investment case rests on the proposition that a novel mechanism of action may deliver meaningful benefit in patient groups with limited options, while also supporting label expansion and broader physician adoption. That creates an attractive upside scenario, but it also means execution risk remains high: the company depends on clinical outcomes, commercial uptake, reimbursement, and the ability to sustain momentum against larger oncology players.
Geographically, Geron’s current commercial footprint is primarily in the United States, with recent company communications indicating plans for selective European Union launches beginning in 2026. Recent highlights include continued growth in RYTELO net product revenue through 2025 and into early 2026, alongside ongoing development activity in myelofibrosis. The company has also emphasized its intention to strengthen commercial execution, expand awareness among prescribers, and build the foundation for possible portfolio expansion. For investors in Europe, Geron is therefore best viewed as a Nasdaq-listed U.S. biotech with a commercial asset, a focused pipeline, and a catalyst-driven profile that remains highly dependent on adoption and clinical readouts.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
